Construction of a non-toxigenic Escherichia coli oral vaccine strain expressing large amounts of CS6 and inducing strong intestinal and serum anti-CS6 antibody responses in mice

Vaccine

Volumn 29, Issue 48, 2011, Pages 8863-8869

  Tobias, Joshua ^a   Svennerholm, Ann Mari ^a   Carlin, Nils I A ^b   Lebens, Michael ^a   Holmgren, Jan ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b Etvax AB   (Sweden)

Author keywords

CS6; ETEC; Immunogenicity; Mucosal; Vaccine

Indexed keywords

BACTERIAL ANTIGEN; C 600 CS6; C600 COLI SURFACE ANTIGEN 6 VACCINE; COLI SURFACE ANTIGEN 6; ESCHERICHIA COLI VACCINE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; PHENOL; THY ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; BACTERIAL STRAIN; BLOOD ANALYSIS; CONTROLLED STUDY; ENTEROTOXIGENIC ESCHERICHIA COLI; FECES ANALYSIS; FEMALE; IMMUNIZATION; IMMUNOGENICITY; INTESTINE MUCOSA; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; ANTIGENS, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; ESCHERICHIA COLI VACCINES; FEMALE; FORMALDEHYDE; GENETIC VECTORS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTESTINES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PHENOL;

EID: 82455167969     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.09.096     Document Type: Article

References (31)

1. Qadri F., Svennerholm A.-M., Farouque A.S.G., Sack R.B. Enterotoxigenic Escherichia coli in developing countries: epidemiology, microbiology, clinical features, treatment, and prevention. Clin Microbiol Rev 2005, 18:465-483.
2. Gaastra W., Svennerholm A.-M. Colonization factors of human enterotoxigenic Escherichia coli (ETEC). Trends Microbiol 1996, 4:444-452.
3. Jansson L., Tobias J., Lebens M., Svennerholm A.-M., Teneberg S. The major subunit, CfaB, of colonization factor antigen I from enterotoxigenic Escherichia coli is a glycosphingolipid binding protein. Infect Immun 2006, 74:3488-3497.
4. Jansson L., Tobias J., Jarefjäll C., Lebens M., Svennerholm A.-M., Teneberg S. Sulfatide recognition by colonization factor antigen CS6 from Enterotoxigenic Escherichia coli. PLoS One 2009, 4:e4487.
5. Sack R.B. Enterotoxigenic Escherichia coli: identification and characterization. J Infect Dis 1980, 142:279-286.
6. Helander A., Grewal H.M., Gaastra W., Svennerholm A.-M. Detection and characterization of the coli surface antigen 6 of enterotoxigenic Escherichia coli strains by using monoclonal antibodies. J Clin Microbiol 1997, 35:867-872.
7. Tobias J., Lebens M., Källgård S., Nicklasson M., Svennerholm A.-M. Role of different genes in the CS6 operon for surface expression of enterotoxigenic Escherichia coli colonization factor CS6. Vaccine 2008, 26:5373-5380.
8. Shaheen H.I., Khalil S.B., Rao M.R., Abu Elyazeed R., Wierzba T.F., Peruski L.F., et al. Phenotypic profiles of enterotoxigenic Escherichia coli associated with early childhood diarrhea in rural Egypt. J Clin Microbiol 2004, 42:5588-5595.
9. Sack D.A., Shimko J., Torres O., Bourgeois A.L., Francia D.S., Gustafsson B., et al. Randomised, double-blind, safety and efficacy of killed oral vaccine for enterotoxigenic E. coli diarrhoea of travellers to Guatemala and Mexico. Vaccine 2007, 25:4392-4400.
10. Güereña-Burgueño F., Hall E.R., Taylor D.N., Cassels F.J., Scott D.A., Wolf M.K., et al. Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infect Immun 2002, 70:1874-1880.
11. Katz D.E., DeLorimier A.J., Wolf M.K., Hall E.R., Cassels F.J., Van Hamont J.E., et al. Oral immunization of adult volunteers with microencapsulated enterotoxigenic Escherichia coli (ETEC) CS6 antigen. Vaccine 2003, 21:341-346.
12. Tobias J., Holmgren J., Hellman M., Nygren E., Lebens M., Svennerholm A.-M. Over-expression of major colonization factors of enterotoxigenic Escherichia coli, alone or together, on non-toxigenic E. coli bacteria. Vaccine 2010, 28:6977-6984.
13. Levine M.M., Giron J.A., Noriega F. Fimbrial vaccines. Fimbriae: adhesion, biogenics, genetics and vaccines 1994, 255-270. CRC Press, Boca Raton, Fla. P. Klemm (Ed.).
14. Svennerholm A.-M., Tobias J. Vaccines against enterotoxigenic Escherichia coli. Expert Rev Vaccines 2008, 7:795-804.
15. Svennerholm A.-M., Glenn G. Vaccines against enterotoxigenic Escherichia coli. New generation vaccines 2010, 714-722. Informa Healthcare USA, Inc. 4th ed. M.M. Levine, G. Dougan, M.F. Good, M.A. Liu, J.G. Nabel, J.P. Nataro, R. Rappuoli (Eds.).
16. Qadri F., Ahmed T., Ahmed F., Bradley Sack R., Sack D.A., Svennerholm A.-M. Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi children 18-36 months of age. Vaccine 2003, 21:2394-2403.
17. Svennerholm A.-M., Steele D. Microbial-gut interactions in health and disease. Progress in enteric vaccine development. Best Pract Res Clin Gastroenterol 2004, 18:421-445. [Farthing M, editor].
18. Walker R.I., Steele D., Aguado T. Analysis of strategies to successfully vaccinate infants in developing countries against enterotoxigenic E. coli (ETEC) disease. Vaccine 2007, 25:2545-2566.
19. Savarino S.J., Hall E.R., Bassily S., Wierzba T.F., Youssef F.G., Peruski L.F., et al. Introductory evaluation of an oral, killed whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Egyptian infants. Pediatr Infect Dis J 2002, 21:322-330.
20. Qadri F., Ahmed T., Ahmed F., Begum Y.A., Sack D.A., Svennerholm A.-M. Reduced doses of oral killed enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine is safe and immunogenic in Bangladeshi infants 6-17 months of age: dosing studies in different age groups. Vaccine 2006, 24:1726-1733.
21. Tobias J., Lebens M., Bölin I., Wiklund G., Svennerholm A.-M. Construction of non-toxic Escherichia coli and Vibrio cholerae strains expressing high and immunogenic levels of enterotoxigenic E. coli colonization factor I fimbriae. Vaccine 2008, 26:743-752.
22. Evans D.G., Evans D.J., Clegg S., Pauley J.A. Purification and characterization of the CFA/I antigen of enterotoxigenic Escherichia coli. Infect Immun 1979, 25:738-748.
23. Nicklasson M., Sjöling A., Lebens M., Tobias J., Janzon A., Brive L., et al. Mutations in the periplasmic chaperone leading to loss of surface expression of the colonization factor CS6 in enterotoxigenic Escherichia coli (ETEC) clinical isolates. Microb Pathog 2008, 44:246-254.
24. Nygren E., Holmgren J., Attridge S.R. Murine antibody responses following systemic or mucosal immunization with viable or inactivated Vibrio cholerae. Vaccine 2008, 26:6784-6790.
25. Villavedra M., Carol H., Hjulstrom M., Holmgren J., Czerkinsky C. PERFEXT: a direct method for quantitative assessment of cytokine production in vivo at the local level. Res Immunol 1997, 148:257-266.
26. Rudin A., Svennerholm A.-M. Colonization factor antigens (CFAs) of enterotoxigenic Escherichia coli can prime and boost immune responses against heterologous CFAs. Microb Pathog 1994, 16:131-139.
27. Holmgren J, Svennerholm A-M. Patent: Preparation and use of formalin-killed colonization-factor antigen (CFA)-expressing E. coli organisms for vaccination against enteric infection/diarrhea caused by enterotoxigenic E. coli bacteria in humans. Publication nr. WO/1992/014487. International Application nr. PCT/SE1992/000110; 1992.
28. Qadri F., Ahmed T., Ahmed F., Bhuiyan M.S., Mostofa M.G., Cassels F.J., et al. Mucosal and systemic immune responses in patients with diarrhea due to CS6-expressing enterotoxigenic Escherichia coli. Infect Immun 2007, 75:2269-2274.
29. De Lorimier A.J., Byrd W., Hall E.R., Vaughan W.M., Tang D., Roberts Z.J., et al. Murine antibody response to intranasally administered enterotoxigenic Escherichia coli colonization factor CS6. Vaccine 2003, 1:2548-2555.
30. Wyatt B., Cassels F.J. Intranasal immunization of BALB/c mice with enterotoxigenic Escherichia coli colonization factor CS6 encapsulated in biodegradable poly(dl-lactide-co-glycolide) microspheres. Vaccine 2006, 24:1359-1366.
31. McConnell M.M., Thomas L.V., Willshaw G.A., Smith H.R., Rowe B. Genetic control and properties of coli surface antigens of colonization factor antigen IV (PCF8775) of enterotoxigenic Escherichia coli. Infect Immun 1988, 56:1974-1980.